pH-Responsive hyaluronic acid-enveloped ZIF-8 nanoparticles for anti-atherosclerosis therapy

作者全名："Obaid, Essam Abdo Mohammed Saad; Wu, Shuai; Zhong, Yuan; Yan, Meng; Zhu, Li; Li, Bibo; Wang, Yi; Wu, Wei; Wang, Guixue"

作者地址："[Obaid, Essam Abdo Mohammed Saad; Wu, Shuai; Zhong, Yuan; Yan, Meng; Zhu, Li; Wang, Yi; Wu, Wei; Wang, Guixue] Chongqing Univ, Key Lab Biorheol & Technol, State & Local Joint Engn Lab Vasc Implants, Minist Educ,Modern Life Sci Expt Teaching Ctr,Bio, Chongqing 400030, Peoples R China; [Li, Bibo] Chongqing Peoples Hosp, Dept Oncol, Chongqing 401147, Peoples R China; [Wang, Yi] Chongqing Med Univ, Coll Basic Med Sci, Chongqing 400016, Peoples R China"

通信作者："Wang, Y; Wu, W; Wang, GX (通讯作者)，Chongqing Univ, Key Lab Biorheol & Technol, State & Local Joint Engn Lab Vasc Implants, Minist Educ,Modern Life Sci Expt Teaching Ctr,Bio, Chongqing 400030, Peoples R China.; Wang, Y (通讯作者)，Chongqing Med Univ, Coll Basic Med Sci, Chongqing 400016, Peoples R China."

来源：BIOMATERIALS SCIENCE

ESI学科分类：MATERIALS SCIENCE

WOS号：WOS:000827801000001

JCR分区：Q2

影响因子：6.6

年份：2022

卷号：10

期号：17

开始页：4837

结束页：4847

文献类型：Article

关键词：　

摘要："Nanomedicines represent new promising strategies for treating atherosclerosis (AS), because they enhance drug bioavailability and have lower side effects. Nevertheless, nanomedicines have several challenges with these advantages, including a limited circulation life, lack of precise targeting, and insufficient control of drug release. Accordingly, the development of drug delivery systems (DDSs) with abilities to enhance the payload delivery to the AS plaque lesion and to control drug release can boost the therapeutic efficacy and safety for AS treatment. Herein, we employed a one-step self-assembly approach for effectively encapsulating the anti-AS drug simvastatin (SIM) in zeolitic imidazolate framework-8 (ZIF-8) (SIM/ZIF-8), and then coated it with hyaluronic acid (HA) to fabricate the SIM/ZIF-8@HA nanoplatform. The resulting nanoplatform could efficiently accumulate in plaque regions through the specific recognition between HA and CD44. Meanwhile, the acid environment breaks down ZIF-8 to release SIM. The in vitro and in vivo experiments demonstrated that SIM/ZIF-8@HA could inhibit the proliferation of smooth muscle cells and have good biocompatibility. Moreover, SIM/ZIF-8@HA can effectively suppress the development of AS plaques without any considerable side effects in mice treatments. The findings revealed that SIM/ZIF-8@HA may be a promising nanomedicine for safe and efficient anti-AS applications."

基金机构："National Natural Science Foundation of China [31971301, 32171324, 12032007]; Chongqing Science and Technology Bureau [cstc2021jcyj-msxmX0149, cstc2019jcyj-zdxmX0028, cstc2020jscx-msxmX0132]; Chongqing Science and Health Joint Medical Research Project [2019MSXM035]"

基金资助正文："This work was supported by grants from the National Natural Science Foundation of China (31971301, 32171324, and 12032007), the Chongqing Science and Technology Bureau (cstc2021jcyj-msxmX0149, cstc2019jcyj-zdxmX0028, and cstc2020jscx-msxmX0132), and the Chongqing Science and Health Joint Medical Research Project (2019MSXM035). We gratefully thank the Analysis and Testing Center of Chongqing University which provided us with some large instruments and equipment."